Sarepta Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	2,414	1,902	1,243	933.01	701.89	540.1
Revenue Growth (YoY)	47.15%	52.97%	33.26%	32.93%	29.95%	41.82%
Cost of Revenue	1,970	1,124	1,028	1,017	862.13	785.63
Gross Profit	443.83	778.36	215.61	-84.07	-160.24	-245.53
Selling, General & Admin	527.29	557.87	481.87	451.42	282.66	317.88
Amortization of Goodwill & Intangibles	2.55	2.41	1.56	0.71	0.71	0.66
Operating Expenses	529.84	560.28	483.43	452.14	283.37	318.54
Operating Income	-86.01	218.08	-267.82	-536.2	-443.61	-564.06
Interest Expense	-21.77	-18.39	-22.01	-53.25	-63.53	-59.95
Interest & Investment Income	30.58	30.64	36.26	16.49	0.35	2.97
Other Non Operating Income (Expenses)	-4.29	-2.85	0.62	-6.92	-0.94	0.52
EBT Excluding Unusual Items	-81.5	227.48	-252.96	-579.88	-507.72	-620.52
Merger & Restructuring Charges	-40.51	-	-	-	-	-
Gain (Loss) on Sale of Investments	-3.39	41.13	19.39	8.66	-4.33	4.49
Gain (Loss) on Sale of Assets	-	-	102	-	102	108.07
Asset Writedown	-	-	-	-	-	-0.1
Other Unusual Items	-126.79	-7.84	-388.53	-118.74	-8.9	-45
Pretax Income	-252.19	260.77	-520.1	-689.96	-418.95	-553.07
Income Tax Expense	19.33	25.54	15.88	13.53	-0.17	1.06
Net Income	-271.51	235.24	-535.98	-703.49	-418.78	-554.13
Net Income to Common	-271.51	235.24	-535.98	-703.49	-418.78	-554.13
Shares Outstanding (Basic)	98	95	92	88	81	78
Shares Outstanding (Diluted)	98	108	92	88	81	78
Shares Change (YoY)	-2.62%	16.75%	5.53%	7.75%	4.24%	5.90%
EPS (Basic)	-2.77	2.47	-5.80	-8.03	-5.15	-7.11
EPS (Diluted)	-2.77	2.34	-5.80	-8.03	-5.15	-7.11
Free Cash Flow	-381.1	-342.74	-577.1	-356.17	-481.66	25.26
Free Cash Flow Per Share	-3.89	-3.18	-6.25	-4.07	-5.93	0.32
Gross Margin	18.39%	40.92%	17.34%	-9.01%	-22.83%	-45.46%
Operating Margin	-3.56%	11.47%	-21.54%	-57.47%	-63.20%	-104.44%
Profit Margin	-11.25%	12.37%	-43.11%	-75.40%	-59.66%	-102.60%
Free Cash Flow Margin	-15.79%	-18.02%	-46.41%	-38.17%	-68.62%	4.68%
EBITDA	-36.28	255.81	-223.43	-494.34	-405.59	-537.6
EBITDA Margin	-1.50%	13.45%	-17.97%	-52.98%	-57.79%	-99.54%
D&A For EBITDA	49.72	37.72	44.4	41.86	38.02	26.46
EBIT	-86.01	218.08	-267.82	-536.2	-443.61	-564.06
EBIT Margin	-3.56%	11.47%	-21.54%	-57.47%	-63.20%	-104.44%
Effective Tax Rate	-	9.79%	-	-	-	-
Revenue as Reported	2,414	1,902	1,243	933.01	701.89	540.1
Advertising Expenses	-	32	28.6	14.6	7.7	-

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q